小児用肺炎球菌治療薬市場：製品タイプ、年齢層、疾患タイプ、投与方法、治療用途、エンドユーザー別-2025-2030年世界予測

小児用肺炎球菌治療薬市場は、2024年には121億8,000万米ドルとなり、2025年には131億5,000万米ドル、CAGR 8.14%で成長し、2030年には194億9,000万米ドルに達すると予測されています。

近年、小児用肺炎球菌治療薬は、新たな研究、高度な技術、病原体の動態の深い理解に後押しされ、大きな変革期を迎えています。新規治療アプローチの開発は、臨床転帰を改善するだけでなく、小児の呼吸器感染症に対する予防戦略の強化も促進しています。このイントロダクションでは、現在の治療環境を包括的に概観し、小児における肺炎球菌感染症への取り組みにおいて、技術革新とデータに基づいた洞察が果たす極めて重要な役割について概説します。

肺炎球菌感染症は、長年のワクチン接種と治療レジメンにもかかわらず、世界的に小児の罹患率と死亡率の主な原因の1つとなっています。このような感染症の負担が世界のヘルスケアシステムに対する課題を続ける中、予防対策と高度な治療介入の両方を統合する再定義されたアプローチが不可欠となっています。臨床医、調査研究者、ヘルスケア政策立案者のすべてが、最先端の科学と市場情報を活用し、効果的で長期にわたって持続可能なソリューションを調整する必要性に注目しています。

戦略を適応させる必要性は、小児病原体特有の複雑さと肺炎球菌感染症の多様な臨床症状から生じます。本書はエビデンスに基づく実践に焦点を当て、治療状況を変えつつある動向、革新、戦略的市場シフトを明らかにし、最終的に患者の転帰改善とより効率的なヘルスケア管理に貢献することを目指します。この分野では、従来の治療パラダイムから、統合された患者中心のアプローチへと転換する中で、実用的な洞察に重点を置いています。

研究と治療の現状を理解することで、利害関係者は小児の肺炎球菌感染症と闘うために行われている多角的な取り組みをより理解することができます。この後の議論は、新たな動向、競合考察、地域力学、競合環境の徹底的な調査から成り、これら全てが小児ヘルスケアに有望な未来をもたらすものです。

小児用肺炎球菌治療薬における変革的変化

近年、小児用肺炎球菌治療薬へのアプローチは、バイオテクノロジーの進歩、規制の枠組みの進化、新しい臨床ガイドラインなどにより、大きく変化しています。治療市場は現在、感染症に対する消極的な治療から、精密な医薬品や個人に合わせた免疫戦略による積極的な管理へと重点が移され、パラダイムシフトを経験しています。

薬物療法の進化は、従来の抗生物質治療にとどまらない革新の波をもたらしました。新しいメカニズムに基づく治療法、特に特定の細菌の病原性因子を同定して標的とする治療法が、有望な選択肢として浮上してきました。これと並行して、肺炎球菌感染症に対する世界の闘いでは、ワクチン開発が中心となっています。子どもたちに提供される免疫防御のスペクトルを広げるため、結合型や多糖類の製剤を活用し、ワクチンはますます洗練されてきています。このように治療と予防の両面に重点を置くことで、さまざまな臨床症状や病原体株によってもたらされる複雑な事態にしっかりと対応することができます。

情勢における最も大きな変化のひとつは、個別化医療の統合に関するものです。遺伝子プロファイリングやバイオマーカーの同定を通じて、治療はよりカスタマイズされ、抗生物質耐性や副作用の可能性を減らし、同時に予防接種スケジュールの有効性を高めています。個別化された治療戦略へのシフトは、個々の患者のユニークなニーズに対応するだけでなく、感染症の負担軽減を目的とした世界のヘルスケア政策にも合致しています。

デジタルヘルスと高度なアナリティクスは、臨床現場における意思決定をさらに変革しました。統合医療情報システムにより、医療従事者は患者の転帰をリアルタイムでモニターし、治療プロトコルを迅速に調整し、疫学的動向をより正確に追跡できるようになりました。これらの技術は、治療アルゴリズムを改良し、小児患者が最も適切でタイムリーな治療を受けられるようにするために大きく貢献しています。

サマリーをまとめると、小児用肺炎球菌治療における変革的なシフトは、革新的な医薬品開発、高度なワクチン技術、デジタルヘルスソリューションの融合によって特徴付けられます。これらの要素は総合的にヘルスケアプロバイダーに力を与え、肺炎球菌感染症に苦しむ小児に対する患者の安全性、有効性の向上、適応性のある治療法を優先する、再構築された積極的な治療状況に貢献しています。

小児用肺炎球菌治療薬の主要セグメントに関する洞察

小児用肺炎球菌治療薬市場の正確な理解は、詳細なセグメンテーション分析によって最もよく達成されます。この市場は、治療製品の性質、年齢コホート、疾患のタイプ、投与方法、侵襲的・非侵襲的状態における用途、エンドユーザー設定など、いくつかの観点から分析することができます。

製品ベースのセグメンテーションでは、医薬品とワクチンが区別されます。医薬品分野では、従来の薬物療法が依然として感染症対策に不可欠である一方、ワクチン分野は結合型ワクチンと多糖類ワクチンに深く分類され、進化を続けています。これらのワクチンにはそれぞれ異なる免疫原性プロファイルがあり、結合型ワクチンは従来の製剤に比べ、幼児においてより強固な免疫反応を示します。

年齢層という観点から市場を検討する場合、乳幼児が主な対象となります。免疫学的な成熟度や感染症に対する感受性は、このような幼い集団によって大きく異なるため、この区別は不可欠であり、それによってオーダーメイドの治療レジメンが導き出されます。

疾患の類型を考慮し、治療市場は細菌性肺炎、マイコプラズマ肺炎、ウイルス性肺炎について調査しています。これらの臨床症状はそれぞれ独自の治療経路を必要とします。細菌性肺炎はその進行がより重篤なことが多く、積極的かつタイムリーな介入が必要であるのに対し、マイコプラズマ肺炎やウイルス性肺炎は支持療法や特定の抗ウイルスレジメンを含む別の管理戦略を必要とすることがあります。

もう一つの重要な点は投与方法です。治療方法には、筋肉内、鼻腔内、静脈内、経口などいくつかの選択肢があります。これらの方法にはそれぞれ利点と限界があり、ドラッグデリバリーのスピードと患者のコンプライアンスに影響を与えます。一方、経口投与は容易であるため、外来患者における治療プロトコールの遵守をサポートします。

治療用途により、市場は侵襲性肺炎球菌感染症治療と非侵襲性肺炎球菌感染症治療にさらに細分化されます。前者には菌血症や髄膜炎などの重篤な疾患が含まれ、迅速かつ強力な介入が重要です。一方、中耳炎や副鼻腔炎などの非侵襲性肺炎球菌性疾患は、重症度は低いもの、合併症を予防しQOLを向上させるために慎重な管理が必要です。

治療が提供される環境もまた、セグメンテーションのレイヤーを提供します。エンドユーザーは、診療所や病院から在宅医療まで多岐にわたるが、これは、小児医療が実施されるさまざまな状況や、治療へのアクセスに影響を及ぼす多様な経済的原動力を反映しています。

これらのセグメント化された洞察を総合すると、多面的でダイナミックな市場であることがわかる。こうした側面を理解することで、利害関係者は小児集団内の特定のニーズをターゲットとし、治療プロトコルが効果的であるだけでなく、臨床と在宅ケアの両方の現実的な環境に適合するように調整されることを保証することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 親とヘルスケア従事者の間で肺炎球菌感染症に対する意識が高まっている
    • 混合ワクチンの採用増加により小児用肺炎球菌薬が増加
    • ワクチン接種と予防ヘルスケアを推進する政府の取り組みと政策
  • 抑制要因
    • 研究開発にかかるコストが高いため、新規参入が制限される
  • 機会
    • さまざまな年齢層の小児に適応できるよう、年齢に応じた処方を開発する
    • 遠隔医療技術への投資でリーチを拡大し、患者の転帰を改善する
  • 課題
    • 小児における薬物試験に関する高まる倫理的懸念と透明性の要求に応える
• 市場セグメンテーション分析
  • 製品：乳児に対する効果が実証されているため、結合ワクチンの採用が増加
  • 治療への応用：侵襲性肺炎球菌性疾患における小児用肺炎球菌治療薬の応用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 小児用肺炎球菌治療薬市場：製品別

• 薬
• ワクチン
  • 結合ワクチン
  • 多糖類ワクチン

第7章 小児用肺炎球菌治療薬市場：年齢層別

• 乳児
• 幼児

第8章 小児用肺炎球菌治療薬市場：疾患タイプ別

• 細菌性肺炎
• マイコプラズマ肺炎
• ウイルス性肺炎

第9章 小児用肺炎球菌治療薬市場投与方法別

• 筋肉内
• 鼻腔内
• 静脈内
• オーラル

第10章 小児用肺炎球菌治療薬市場治療アプリケーション

• 侵襲性肺炎球菌感染症
  • 菌血症
  • 髄膜炎
• 非侵襲性肺炎球菌性疾患
  • 中耳炎
  • 副鼻腔炎

第11章 小児用肺炎球菌治療薬市場：エンドユーザー別

• クリニック
• ホームケア設定
• 病院

第12章 南北アメリカの小児用肺炎球菌治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の小児用肺炎球菌治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの小児用肺炎球菌治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Aurobindo Pharma Limited
• Baxter International Inc.
• Bharat Biotech International Limited
• Biocon Limited
• BioNTech SE
• CanSino Biologics Inc.
• CSL Limited
• Daiichi Sankyo Company, Limited
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals
• Hoffmann-La Roche AG
• Johnson & Johnson
• Lupin Limited
• Merck & Co., Inc.
• Moderna, Inc.
• Novartis AG
• Novavax, Inc.
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Zydus Cadila

LIST OF FIGURES

• FIGURE 1. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET MULTI-CURRENCY
• FIGURE 2. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET MULTI-LANGUAGE
• FIGURE 3. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 4. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DRUG, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY BACTERIAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VIRAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY BACTEREMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY SINUSITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 68. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 69. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 72. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 73. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 74. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 91. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 100. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 102. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 107. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 110. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 111. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 112. AUSTRALIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 115. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 116. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 119. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 120. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 121. CHINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 124. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 125. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 128. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 129. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 130. INDIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 133. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 134. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 137. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 138. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 139. INDONESIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 142. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 143. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 144. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 146. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 147. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 148. JAPAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 151. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 152. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 153. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 155. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 156. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 157. MALAYSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 159. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 160. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 161. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 164. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 165. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 166. PHILIPPINES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 169. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 170. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 173. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 174. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 175. SINGAPORE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 178. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 179. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 180. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 182. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 184. SOUTH KOREA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 187. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 188. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 189. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 191. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 192. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 193. TAIWAN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 196. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 197. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 198. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 200. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 201. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 202. THAILAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 204. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 205. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 206. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 207. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 209. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 210. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 211. VIETNAM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 222. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 223. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 224. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 225. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 226. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 227. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 228. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 229. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 230. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 232. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 233. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 234. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 235. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 237. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 238. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 239. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 240. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 241. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 242. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 243. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 244. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 245. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 246. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 247. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 248. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 249. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 250. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 251. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 252. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 253. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 254. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 255. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 256. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 257. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 258. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 259. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 260. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 261. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 262. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 263. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 264. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 265. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 266. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 268. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 269. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 270. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 271. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 272. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 273. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 274. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 275. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 276. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 277. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
• TABLE 278. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 279. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 280. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 281. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 282. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 283. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
• TABLE 284. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY

The Pediatrics Pneumococcal Therapeutics Market was valued at USD 12.18 billion in 2024 and is projected to grow to USD 13.15 billion in 2025, with a CAGR of 8.14%, reaching USD 19.49 billion by 2030.

In recent years, pediatric pneumococcal therapeutics have undergone a significant transformation, driven by emerging research, advanced technologies, and a deeper understanding of pathogen dynamics. The development of novel therapeutic approaches has not only improved clinical outcomes but has also fostered enhanced preventive strategies against respiratory infections in children. This introduction provides a comprehensive overview of the current therapeutic environment, outlining the pivotal role of innovation and data-driven insights in addressing pneumococcal diseases in the pediatric population.

Pneumococcal infections remain one of the leading causes of childhood morbidity and mortality worldwide, despite longstanding vaccination and treatment regimens. As the burden of these infections continues to challenge healthcare systems globally, a redefined approach that integrates both preventive measures and advanced therapeutic interventions has become indispensable. Clinicians, researchers, and healthcare policymakers are all converging on the need to harness cutting-edge science and market intelligence to tailor solutions that are both effective and sustainable over time.

The necessity to adapt strategies arises from the inherent complexity of pediatric pathogens and the diverse clinical manifestations of pneumococcal diseases. With a focus on evidence-based practice, this narrative seeks to illuminate the trends, innovations, and strategic market shifts that are reshaping the therapeutic landscape, ultimately contributing to improved patient outcomes and more efficient healthcare management. Emphasis is placed on actionable insights as the sector pivots from traditional treatment paradigms in favor of integrated, patient-centric approaches.

By understanding the current state of research and therapy, stakeholders can better appreciate the multi-dimensional efforts underway to combat pneumococcal diseases in children. The discussions that follow comprise a thorough exploration of emerging trends, segmentation insights, regional dynamics, and the competitive environment, all of which signal a promising future for pediatric healthcare.

Transformative Shifts in Pediatric Pneumococcal Therapeutics

Recent years have witnessed transformative shifts in the approaches to pediatric pneumococcal therapeutics, driven by advancements in biotechnology, evolving regulatory frameworks, and novel clinical guidelines. The therapeutic market is now experiencing a paradigm shift as emphasis moves from reactive treatment of infections towards proactive management with precision medicines and tailored immunization strategies.

The evolution of drug therapies has brought a wave of innovation that extends beyond traditional antibiotic treatments. Newer, mechanism-based therapies, particularly those that identify and target specific bacterial virulence factors, have emerged as promising alternatives. In parallel, vaccine development has taken center stage in the global fight against pneumococcal diseases. Vaccines have become increasingly sophisticated, leveraging conjugate and polysaccharide formulations to broaden the spectrum of immune protection offered to children. This dual focus on both therapeutics and preventive measures ensures a robust response to the complexities presented by varying clinical presentations and pathogen strains.

One of the most significant changes in the landscape relates to the integration of personalized medicine. Through genetic profiling and biomarker identification, treatments are becoming more customized, reducing the likelihood of antibiotic resistance and adverse reactions, while enhancing the effectiveness of immunization schedules. The shift towards personalized treatment strategies not only caters to the unique needs of individual patients but also aligns with global healthcare policies aimed at reducing the burden of infectious diseases.

Digital health and advanced analytics have further transformed decision-making within clinical settings. Integrated health information systems allow practitioners to monitor patient outcomes in real time, adjust therapeutic protocols promptly, and track epidemiological trends more accurately. These technologies contribute significantly to refining treatment algorithms and ensuring that pediatric patients receive the most appropriate and timely care.

In summary, the transformative shifts in pediatric pneumococcal therapeutics are characterized by the convergence of innovative drug development, advanced vaccine technologies, and digital health solutions. These elements collectively empower healthcare providers, contributing to a reimagined and proactive therapeutic landscape that prioritizes patient safety, improved efficacy, and adaptive treatment modalities for children suffering from pneumococcal diseases.

Key Segmentation Insights in Pediatric Pneumococcal Therapeutics

A nuanced understanding of the pediatric pneumococcal therapeutics market is best achieved through detailed segmentation analysis. The market can be analyzed from several perspectives including the nature of the therapeutic product, age cohort, type of disease, mode of administration, applications in invasive and non-invasive conditions, and the end-user setting.

The product-based segmentation distinguishes between pharmaceuticals and vaccines. In the pharmaceutical segment, traditional drug therapies remain integral to immediate infection control, while the vaccine segment continues to evolve with its deeper categorization into conjugate vaccines and polysaccharide vaccines. These vaccine types offer distinct immunogenic profiles, with conjugate vaccines providing a more robust immune response in young children compared to traditional formulations.

When examining the market through the lens of age groups, the primary segments under review include infants and toddlers. This distinction is essential, as immunological maturity and the susceptibility to infections vary significantly between these young cohorts, thereby informing tailored therapeutic regimens.

Considering the disease typology, the therapeutic market is studied with reference to bacterial pneumonia, mycoplasma pneumonia, and viral pneumonia. Each of these clinical presentations demands a unique treatment pathway. Bacterial pneumonia, often more severe in its progression, necessitates aggressive and timely intervention, whereas mycoplasma and viral pneumonia may require alternative management strategies including supportive care and specific antiviral regimens.

Another crucial dimension is the mode of administration. Treatment modalities encompass several options including intramuscular, intranasal, intravenous, and oral routes. Each of these methods presents its own set of benefits and limitations, influencing both the speed of drug delivery and patient compliance. Intramuscular injections often deliver rapid systemic effects, while the ease of oral administration supports adherence to treatment protocols in outpatient settings.

Therapeutic applications further segment the market into treatments for invasive pneumococcal diseases and non-invasive pneumococcal diseases. The former includes serious conditions like bacteremia and meningitis, where swift and potent intervention is critical. Conversely, non-invasive conditions such as otitis media and sinusitis, though less severe, still require careful management to prevent complications and promote quality of life.

The setting in which treatment is rendered also provides a layer of segmentation. End-users range from clinics and hospitals to homecare settings, reflecting the varied contexts in which pediatric care is administered and the diverse economic dynamics influencing therapeutic access.

Collectively, these segmented insights underscore a market that is multifaceted and dynamic. Understanding these dimensions allows stakeholders to target specific needs within the pediatric population, ensuring that therapeutic protocols are not only effective but also tailored to meet the practical realities of both clinical and homecare environments.

Based on Product, market is studied across Drug and Vaccine. The Vaccine is further studied across Conjugate Vaccine and Polysaccharide Vaccine.

Based on Age Group, market is studied across Infants and Toddlers.

Based on Disease Type, market is studied across Bacterial Pneumonia, Mycoplasma Pneumonia, and Viral Pneumonia.

Based on Mode of Administration, market is studied across Intramuscular, Intranasal, Intravenous, and Oral.

Based on Therapeutic Applications, market is studied across Invasive Pneumococcal Diseases and Non-Invasive Pneumococcal Diseases. The Invasive Pneumococcal Diseases is further studied across Bacteremia and Meningitis. The Non-Invasive Pneumococcal Diseases is further studied across Otitis Media and Sinusitis.

Based on End-User, market is studied across Clinics, Homecare Settings, and Hospitals.

Key Regional Insights on Global Pediatric Pneumococcal Therapeutics Trends

Analyzing regional trends in pediatric pneumococcal therapeutics reveals unique market dynamics and growth opportunities that are shaped by local healthcare infrastructures, regulatory environments, and epidemiological profiles. The market's global evolution can be distilled into insights pertinent to regions such as the Americas, Europe including the Middle East and Africa, and Asia-Pacific.

In the Americas, robust healthcare systems and substantial investments in vaccine research and pharmaceutical innovations have driven significant advancements. Countries with well-established immunization programs have seen marked reductions in pneumococcal disease prevalence, which further spurs demand for novel therapeutic solutions that optimize treatment protocols and reduce the reliance on antibiotics. The increased focus on surveillance and early intervention in these regions is also shaping market strategies and fostering collaborations aimed at expanding pediatric care.

The region encompassing Europe, the Middle East, and Africa exhibits a complex tapestry of challenges and opportunities. European countries typically benefit from high technological readiness and stringent regulatory oversight, which collectively enhance the quality and safety of new therapeutics. In contrast, parts of the Middle East and Africa are experiencing rapid demographic changes and evolving healthcare frameworks, which have created a fertile ground for introducing innovative and adaptable treatment policies. Investments in infrastructure and cross-border healthcare initiatives are broadening access to both vaccines and drug therapies, thereby driving market growth even in resource-limited settings.

Across the Asia-Pacific region, the dynamics of pediatric healthcare are influenced by a combination of high population density, varying levels of economic development, and diverse public health policies. Asia-Pacific markets have witnessed increased domestic production of vaccines and a surge in research collaborations that aim to tailor treatments to local disease profiles. In addition to the rapid urbanization and rising disposable incomes in many countries within this region, there is an ever-growing emphasis on the integration of digital healthcare solutions that facilitate timely diagnosis and efficient treatment delivery.

These regional insights highlight the importance of a localized approach when designing and deploying pediatric pneumococcal therapeutics. Strategic market entrants and incumbents alike must adapt their offerings to the specific regulatory and economic contours of each region, ensuring that innovations developed in one part of the world can be successfully transposed to meet the needs of diverse patient populations globally.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Key Companies in the Therapeutics Market

The competitive environment within pediatric pneumococcal therapeutics is populated by a diverse array of companies, each contributing uniquely to the market dynamics. A thorough competitive analysis reveals that the landscape is characterized by both long-established pharmaceutical giants and innovative biotechnological firms. Prominent companies driving this sector include AbbVie Inc., Astellas Pharma Inc., and AstraZeneca PLC, whose extensive research and development portfolios have enabled them to stay at the forefront of therapeutic innovation.

In addition, companies such as Aurobindo Pharma Limited and Baxter International Inc. have demonstrated strong capabilities in scaling production while ensuring the availability of high-quality drug interventions. Bharat Biotech International Limited and Biocon Limited have also made significant contributions, particularly through their breakthroughs in vaccine development, which have enabled more effective preventative measures against pneumococcal infections.

Biotech disruptors like BioNTech SE and CanSino Biologics Inc. are emerging with novel approaches and agile development cycles, further intensifying competition in the vaccine segment. The presence of well-established entities like CSL Limited, along with firms such as Daiichi Sankyo Company, Limited, and Dr. Reddy's Laboratories Ltd., adds to the market's strategic depth.

Notable players such as Eli Lilly and Company, GlaxoSmithKline plc, and Glenmark Pharmaceuticals bring decades-long expertise in drug formulations and patient care innovations. The landscape is further enriched by global powerhouses like Hoffmann-La Roche AG, Johnson & Johnson, and Lupin Limited, whose focus on ensuring safety and efficacy continues to shape therapeutic trends.

Additional major contributors include Merck & Co., Inc., Moderna, Inc., Novartis AG, and Novavax, Inc., each investing heavily in research that expands the scientific understanding of immune responses in children. Entities like Panacea Biotec Ltd., Pfizer Inc., and Sanofi S.A. have maintained a robust presence in both the drug and vaccine sectors, supported by extensive clinical networks and advanced manufacturing capabilities.

The competitive scene is rounded out by influential firms such as Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Cadila, all of which continue to push the envelope in therapeutic innovations.

Overall, the industry is marked by high levels of competition, with each company leveraging its unique strengths to cater to a broad spectrum of pediatric healthcare needs. Their combined efforts are not only enhancing the quality of care but are also fostering an environment ripe for further scientific exploration and market expansion.

The report delves into recent significant developments in the Pediatrics Pneumococcal Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Bharat Biotech International Limited, Biocon Limited, BioNTech SE, CanSino Biologics Inc., CSL Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Hoffmann-La Roche AG, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Moderna, Inc., Novartis AG, Novavax, Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Cadila. Actionable Recommendations for Industry Leaders in Pediatric Therapeutics

Industry leaders looking to capitalize on the evolving landscape of pediatric pneumococcal therapeutics must adopt a range of strategic actions to secure a competitive edge and ensure sustainable growth. One of the primary recommendations is to invest robustly in research and development initiatives that target both drug and vaccine innovations. Continuous investment in R&D not only accelerates the discovery of novel therapeutic agents but also enhances the refinement of existing products to address emerging resistance patterns and changing epidemiological trends.

Another key recommendation is to foster strategic partnerships that span across academia, biotechnology firms, and clinical institutions. Collaboration facilitates the pooling of expertise, resources, and technological innovation, thereby expediting the development cycle for new products. In a market where time-to-market can be a critical factor, integrated partnerships enable quicker adaptation to regulatory changes and swift dissemination of breakthroughs.

Industry leaders should also focus on enhancing their digital infrastructure. The integration of data analytics, real-time patient monitoring, and advanced diagnostic tools can not only fine-tune treatment protocols but also drive personalized medicine initiatives that cater to the distinctive needs of infants and toddlers. Embracing digital technologies helps ensure that therapeutic solutions remain patient-centric, efficient, and adaptive to real-world challenges.

Furthermore, expanding market outreach in emerging economies presents an untapped opportunity. A geographic focus on regions with evolving healthcare systems - where demand is rising due to increasing awareness and enhanced healthcare funding - can lead to substantial market penetration and revenue growth. By tailoring product portfolios to meet the specific needs identified in varying regional contexts, companies can optimize their market strategies and gain a competitive advantage.

Additionally, regulatory compliance and patient safety must remain at the forefront of strategic operations. Investing in stringent quality control measures and comprehensive clinical trials not only reinforces trust among healthcare providers but also mitigates risks associated with adverse therapeutic effects. In an industry that is under intense scrutiny, adherence to high safety standards and transparent communication with regulatory bodies are critical to sustaining market confidence.

Finally, fostering market education is essential. By developing informative platforms and outreach programs, industry incumbents can better communicate the benefits and innovative nature of new therapeutic approaches, thereby driving adoption among physicians and healthcare practitioners. These educational initiatives should be supported by compelling data and clearly articulated best practices to ensure that advancements in treatments are effectively disseminated across the healthcare continuum.

Adopting these actionable recommendations will equip industry leaders with the insights and tools necessary to navigate the complexities of the pediatric pneumococcal therapeutics market, ensuring a proactive response to both current and future challenges.

Conclusion: Shaping the Future of Pediatric Therapeutics

The evolution of pediatric pneumococcal therapeutics represents a transformative journey marked by innovative breakthroughs, strategic realignments, and a relentless pursuit of improved clinical outcomes. Analysis of the therapeutic landscape has underlined a dynamic interplay between groundbreaking drug developments and the sophisticated evolution of vaccine technologies. This confluence of advanced research, enhanced digital infrastructure, and strategic market segmentation has set the stage for a comprehensive rethinking of pediatric healthcare solutions.

The discussion provided an expansive view of the key areas shaping the market: from the detailed segmentation that distinguishes treatment modalities, age-specific considerations, and disease profiles, to the regional insights that reveal distinctive growth opportunities across the Americas, Europe including the Middle East and Africa, and the Asia-Pacific region. Moreover, competition among leading companies-ranging from established giants to innovative disruptors-illustrates the robust activity and potential for sustained momentum in the market.

In light of these factors, stakeholders can draw significant learnings regarding both the challenges and opportunities that are intrinsic to the field. The insights offered in this analysis support a strategic recalibration that emphasizes personalized medicine, the synergy of cross-sector partnerships, and a dedicated focus on regional diversity in healthcare needs. As the industry continues to evolve, the drive towards innovative, patient-centric solutions will remain a cornerstone of effective therapeutic strategies for pediatric populations worldwide.

Ultimately, the advancements in pediatric pneumococcal therapeutics provide not only a window into the future of treatment and prevention but also a roadmap for how industries can harmonize clinical innovations with market realities. This confluence of strategy and science underscores the promise of a healthier future for children, where precision medicine and proactive interventions stand as bulwarks against the challenges of infectious diseases.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing awareness about pneumococcal diseases among parents and healthcare providers
    • 5.1.1.2. Rising adoption of combination vaccines amplifies pediatric pneumococcal drugs
    • 5.1.1.3. Government initiatives and policies promoting vaccination and preventative healthcare
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with R&D limit the entry of new competitors
  • 5.1.3. Opportunities
    • 5.1.3.1. Developing age-specific formulations to better cater to different pediatric age groups
    • 5.1.3.2. Investing in telemedicine technology to expand reach and improve patient outcomes
  • 5.1.4. Challenges
    • 5.1.4.1. Meeting the growing ethical concerns and transparency demands regarding drug trials in children
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Increasing adoption of conjugate vaccines due to their proven efficacy in infants
  • 5.2.2. Therapeutic Applications: Expanding the application of pediatrics pneumococcal therapeutics in invasive pneumococcal diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pediatrics Pneumococcal Therapeutics Market, by Product

• 6.1. Introduction
• 6.2. Drug
• 6.3. Vaccine
  • 6.3.1. Conjugate Vaccine
  • 6.3.2. Polysaccharide Vaccine

7. Pediatrics Pneumococcal Therapeutics Market, by Age Group

• 7.1. Introduction
• 7.2. Infants
• 7.3. Toddlers

8. Pediatrics Pneumococcal Therapeutics Market, by Disease Type

• 8.1. Introduction
• 8.2. Bacterial Pneumonia
• 8.3. Mycoplasma Pneumonia
• 8.4. Viral Pneumonia

9. Pediatrics Pneumococcal Therapeutics Market, by Mode of Administration

• 9.1. Introduction
• 9.2. Intramuscular
• 9.3. Intranasal
• 9.4. Intravenous
• 9.5. Oral

10. Pediatrics Pneumococcal Therapeutics Market, by Therapeutic Applications

• 10.1. Introduction
• 10.2. Invasive Pneumococcal Diseases
  • 10.2.1. Bacteremia
  • 10.2.2. Meningitis
• 10.3. Non-Invasive Pneumococcal Diseases
  • 10.3.1. Otitis Media
  • 10.3.2. Sinusitis

11. Pediatrics Pneumococcal Therapeutics Market, by End-User

• 11.1. Introduction
• 11.2. Clinics
• 11.3. Homecare Settings
• 11.4. Hospitals

12. Americas Pediatrics Pneumococcal Therapeutics Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Pediatrics Pneumococcal Therapeutics Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Pediatrics Pneumococcal Therapeutics Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Sanofi and SK bioscience advance phase 3 PCV21 program to enhance global pediatric pneumococcal protection
  • 15.3.2. Hong Kong Department of Health approved Pfizer's 20-valent Pneumococcal Conjugate Vaccine
  • 15.3.3. Abbott India launched PneumoShield 14, a new pneumococcal conjugate vaccine
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Astellas Pharma Inc.
• 3. AstraZeneca PLC
• 4. Aurobindo Pharma Limited
• 5. Baxter International Inc.
• 6. Bharat Biotech International Limited
• 7. Biocon Limited
• 8. BioNTech SE
• 9. CanSino Biologics Inc.
• 10. CSL Limited
• 11. Daiichi Sankyo Company, Limited
• 12. Dr. Reddy's Laboratories Ltd.
• 13. Eli Lilly and Company
• 14. GlaxoSmithKline plc
• 15. Glenmark Pharmaceuticals
• 16. Hoffmann-La Roche AG
• 17. Johnson & Johnson
• 18. Lupin Limited
• 19. Merck & Co., Inc.
• 20. Moderna, Inc.
• 21. Novartis AG
• 22. Novavax, Inc.
• 23. Panacea Biotec Ltd.
• 24. Pfizer Inc.
• 25. Sanofi S.A.
• 26. Serum Institute of India Pvt. Ltd.
• 27. Sinovac Biotech Ltd.
• 28. Takeda Pharmaceutical Company Limited
• 29. Teva Pharmaceutical Industries Ltd.
• 30. Zydus Cadila